$21.80
2.44% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
BMG5269C1010
Symbol
KNSA
Sector
Industry

Kiniksa Pharmaceuticals Ltd. Class A Stock price

$21.80
-5.64 20.55% 1M
+2.75 14.44% 6M
+4.26 24.29% YTD
+5.97 37.71% 1Y
+9.67 79.72% 3Y
+11.19 105.47% 5Y
+2.33 11.97% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.52 2.44%
ISIN
BMG5269C1010
Symbol
KNSA
Sector
Industry

Key metrics

Market capitalization $1.57b
Enterprise Value $1.36b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 122.60
EV/Sales (TTM) EV/Sales 3.54
P/S ratio (TTM) P/S ratio 4.10
P/B ratio (TTM) P/B ratio 3.60
Revenue growth (TTM) Revenue growth 54.41%
Revenue (TTM) Revenue $384.10m
EBIT (operating result TTM) EBIT $-26.24m
Free Cash Flow (TTM) Free Cash Flow $11.10m
Cash position $223.78m
EPS (TTM) EPS $-0.14
P/E forward negative
P/S forward 3.71
EV/Sales forward 3.21
Short interest 13.05%
Show more

Is Kiniksa Pharmaceuticals Ltd. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Kiniksa Pharmaceuticals Ltd. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:

Buy
100%

Financial data from Kiniksa Pharmaceuticals Ltd. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
384 384
54% 54%
100%
- Direct Costs 150 150
83% 83%
39%
234 234
40% 40%
61%
- Selling and Administrative Expenses 163 163
45% 45%
42%
- Research and Development Expense 96 96
38% 38%
25%
-25 -25
65% 65%
-6%
- Depreciation and Amortization 1.53 1.53
64% 64%
0%
EBIT (Operating Income) EBIT -26 -26
36% 36%
-7%
Net Profit -9.07 -9.07
36% 36%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Kiniksa Pharmaceuticals Ltd. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kiniksa Pharmaceuticals Ltd. Class A Stock News

Neutral
GlobeNewsWire
14 days ago
LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 12:00 p.m. Greenwich Mean Time (7:00 a.m. Eastern Time).
Neutral
Seeking Alpha
28 days ago
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Sanj Patel - Chairman and Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer John Paolini - Chief Medical Officer Conference Call Participants Roger Song - Jefferies L...
Neutral
GlobeNewsWire
28 days ago
– ARCALYST ® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $410 - $420 million – – Life DisRPted ™ disease awareness campaign for recurrent pericarditis launched in partnership with NHL Hall of Famer, Henrik Lundqvist, and GRAMMY ® Award-winning singer-songwriter, Carly Pearce – – Ki...
More Kiniksa Pharmaceuticals Ltd. Class A News

Company Profile

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.

Head office Bermuda
CEO Sanj Patel
Employees 297
Founded 2015
Website www.kiniksa.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today